Dr Stenkivist replies as follows:

In relation to Dr Paul Silococks comments on observer variation I wish to make the following comment:

The breast cancer classification systems we analysed not only have a poor reproducibility but they also lack clinical value in that they do not take into account rate of recurrence. However, parameters whose measurement is easily reproducible, such as "tumour markers" (CEA etc), DNA distribution among tumour cell nuclei, measures of tumour size, etc, although clearly correlated with prognosis when you compare groups of patients, are of little or no value for prognosis in the individual patient unless they are combined in a reliable way into a malignancy index that can be obtained by step-wise logistic regression analysis. We have recently addressed this problem, and we think it is time that pathologists and clinicians start to look for optimal combinations of parameters to create "malignancy indices" for tumour diseases in order to have practicable methods in daily clinical work.

Breast cancer patients deserve the greatest possible assurance in estimates of the severity of their disease and in the selection of their treatment, just as the clinician should receive the most complete information possible about his patient's condition. Our study indicates that it will be possible to give the clinician such complete information (superior to so-called clinical staging), provided that the significant variables are recorded in a meticulous way and combined into a risk curve. Patients with low malignancy grade as demonstrated in our study could then be confidently reassured that they will not suffer from recurrent disease, and resources for adjuvant therapy and follow-up can be saved for those patients who really need them (ie patients with a high malignancy grade).

Our study further emphasises that there is no evidence that THE factor, a single entity of absolute prognosis, exists or is likely to exist.

We regret our mistake in proof-reading the standard error of kappa of Dr Jacob Cohen's formula. The computation, however, was performed using the correct formula.

Reference

Antinuclear antibody-negative systemic lupus erythematosus—how common?

We read with interest the paper in the October 1982 issue of the Journal. We feel that two factors require further consideration before accepting that 8-9% of patients with SLE may be ANA negative. Firstly, the authors did not test their ANA-negative sera to see whether they would react with human substrates. It is well recognised that a small number of such sera will react only with human tissues such as peripheral granulocytes.

Secondly, our own experience over several years has led us to become increasingly concerned about results obtained with radioimmunoassay kits supplied by RC Amershams. We have found positive anti-DNA results at levels of 30 U/ml or greater, not uncommonly, in sera of patients who have no reliable clinical evidence of SLE as determined by the American Rheumatism Association criteria. Reasons for this may be several and include DNA reactions with basic proteins, binding of Clq to DNA or to low density lipoproteins as well as the possibility that some preparations may contain single stranded DNA. Binding to basic proteins is not uncommon in patients with malignant disease and may be reversed with sodium dodecyl sulphate. Resulting from our dissatisfaction with RIA kits we compared RIA results with those obtained by immunofluorescence using either Crithidia luciliae or human metaphase chromosomes as substrate. Our findings indicate that both immunofluorescence and conventional immunofluorescence with clinical manifestations of SLE and we have now standardised our test procedures on C.luciliae as substrate.

Reference

IgA pyroglobulinaemia in lymphoma

Pyroglobulins are abnormal immunoglobulins, usually IgG or IgM, which when heated to 56°C form a gel irreversible by changes of temperature, pH or dilution. They were first recognised in 1953, and since then have been reported in a variety of conditions, mainly multiple myeloma, Waldenström's macroglobulinaemia, and lymphoma. We would like to report a patient with an unusual pyroglobulin. The patient had abnormal bleeding associated with defective ristocetin-induced platelet aggregation. This appeared to be related to the presence of the abnormal globulin.

When the patient's serum was fractionated to obtain the abnormal pyroglobulin and when this fraction was added to normal plasma it produced a similar defect in platelet aggregation.

Case report

The patient was a 72-year-old woman. Six weeks prior to admission, she complained of arthralgia, involving both ankles, wrists, and knees. She was admitted after the development of a purpuric rash.

On examination, she had a marked purpuric rash over both legs. There was no lymphadenopathy and no hepatomegaly but her spleen was palpable 4-5 cm below

Reference